Mirum Pharmaceuticals, Inc.
40
8
12
21
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 30/100
10.0%
4 terminated/withdrawn out of 40 trials
84.0%
-2.5% vs industry average
28%
11 trials in Phase 3/4
86%
18 of 21 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (40)
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Role: lead
Pediatric Evaluation and Registry for Liver Cholestasis in Canada
Role: collaborator
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
Role: lead
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
Role: lead
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
Role: lead
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Role: lead
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
Role: lead
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
Role: lead
Maralixibat for Intrahepatic Cholestasis of Pregnancy
Role: collaborator
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
Role: lead
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)
Role: lead
MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
Role: lead
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
Role: collaborator
An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
Role: lead
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
Role: lead
Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai
Role: lead
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
Role: lead
Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)
Role: lead
A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)
Role: lead
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
Role: lead